Evaluation of a rapid colorimetric assay for detection of bacterial contamination in apheresis and pooled random-donor platelet units

Transfusion

Volumn 54, Issue 6, 2014, Pages 1634-1641

  Heaton, W Andrew ^a   Good, Caryn E ^b,c   Galloway Haskins, Rakijah ^a   Yomtovian, Roslyn A ^b,d   Jacobs, Michael R ^b,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDOGLYCAN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBODY TITER; APHERESIS; ARTICLE; BACILLUS CEREUS; BACTERIUM CONTAMINATION; BACTERIUM DETECTION; CLOSTRIDIUM PERFRINGENS; COLONY FORMING UNIT; COLORIMETRY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOLOGY TEST KIT; INOCULATION; KLEBSIELLA OXYTOCA; LIMIT OF DETECTION; NONHUMAN; PROPIONIBACTERIUM; PROPIONIBACTERIUM ACNES; PROTEIN ANALYSIS; PSEUDOMONAS AERUGINOSA; RAPID TEST; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; THROMBOCYTE;

BACILLUS CEREUS; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; CLOSTRIDIUM PERFRINGENS; COLORIMETRY; ESCHERICHIA COLI; HUMANS; KLEBSIELLA OXYTOCA; PROPIONIBACTERIUM; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STEM CELLS;

EID: 84902182647     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12603     Document Type: Article

References (28)

1. Dodd R, Kurt Roth W, Ashford P, etal. Transfusion medicine and safety. Biologicals 2009; 37: 62-70.
2. Eder AF, Kennedy JM, Dy BA, etal. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49: 1554-1563.
3. Jacobs MR, Smith D, Heaton WA, etal. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51: 2573-2582.
4. Zou S, Dorsey KA, Notari EP, etal. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504.
5. Zou S, Musavi F, Notari EP, etal. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008. Transfusion 2010; 50: 1487-1494.
6. Zou S, Stramer SL, Notari EP, etal. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49: 1609-1620.
7. Benjamin RJ, Wagner SJ,. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007; 47: 1381-1389.
8. American Association of Blood Banks. Standards for blood banks and transfusion services. 22nd ed. Standard 5.1.5.1. Association Bulletin 03-12, appendix I. 2003.
9. Brecher ME, Jacobs MR, Katz LM, etal. Survey of methods used to detect bacterial contamination of platelet products in the United States in 2011. Transfusion 2013; 53: 911-918.
10. American Association of Blood Banks. Standards for blood banks and transfusion services. 27th ed. Summary of significant changes. 2011 [cited 2013 Oct 4]. Available from: http://www.aabb.org/sa/standards/Documents/ sigchngstds27.pdf
11. FDA. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2012. 2013. [cited 2013 Oct 4]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ ReportaProblem/TransfusionDonationFatalities/ucm346639.htm
12. Eder AF, Kennedy JM, Dy BA, etal. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47: 1134-1142.
13. Murphy WG, Foley M, Doherty C, etal. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95: 13-19.
14. Pearce S, Rowe GP, Field SP,. Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 2011; 21: 25-32.
15. Benjamin RJ, Dy B, Perez J, etal. Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results. Vox Sang 2014; 106: 23-30.
16. Tomasulo PA, Wagner SJ,. Predicting improvement in detection of bacteria in apheresis platelets by maintaining constant component sampling proportion. Transfusion 2013; 53: 835-842.
17. Immunetics. BacTx bacterial detection system. 2013. [cited 2013 Oct 4]. Available from: http://www.immunetics.com/bactx.htm
18. Verax Biomedical. Platelet PGD Test. 2013. [cited 2013 Oct 4]. Available from: http://www.veraxbiomedical.com/products/platelet-pgd-test.asp
19. Kovalenko V, Levin A, Beausang L,. Rapid peptidogycan-based assay for detection of bacterial contamination of platelets. US Patent 7,598,054. 2009. [cited 2013 Oct 4]. Available from: http://www.google.com/patents/US7598054
20. Brecher ME, Blajchman MA, Yomtovian R, etal. Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future. Transfusion 2013; 53: 221-231.
21. American Association of Blood Banks. Public Conference-Secondary Bacterial Screening of Platelet Components, 7/17/12, Bethesda, MD. 2012. [cited 2013 Oct 4]. Available from: http://www.aabb.org/events/misc/Pages/public- conference.aspx
22. FDA. Meeting of the Blood Products Advisory Committee to discuss considerations for strategies to further reduce the risk of bacterial contamination in platelets, Rockville, MD. 2012. [cited 2013 Oct 4]. Available from: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm313863.htm
23. Epstein JS, Vostal JG,. FDA contributions to reduction of bacterial contamination in platelet products within the United States. Transfusion 2013; 53: 232-233.
24. Jacobs MR, Good CE, Lazarus HM, etal. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008; 46: 1214-1220.
25. Vollmer T, Hinse D, Schottstedt V, etal. Inter-laboratory comparison of different rapid methods for the detection of bacterial contamination in platelet concentrates. Vox Sang 2012; 103: 1-9.
26. Brecher ME, Means N, Jere CS, etal. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 2001; 41: 477-482.
27. Kuehnert MJ, Roth VR, Haley NR, etal. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 1493-1499.
28. Murphy WG,. Pathogen reduction: state of reflection in Ireland. Transfus Clin Biol 2011; 18: 488-490.